QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

Rhea-AI Summary

QIAGEN (NYSE: QGEN) reported strong preliminary Q1 2025 results, with net sales growing 7% at constant exchange rates (CER) to approximately $483 million, exceeding the previous outlook of 3% CER growth. Adjusted diluted EPS is expected to be at least $0.55 CER, surpassing the earlier guidance of $0.50 CER.

Key growth drivers include:

• QuantiFERON latent TB test: ~15% CER growth
• QIAstat-Dx syndromic testing system: >35% CER growth
• QIAcuity digital PCR system and QIAGEN Digital Insights: high-single-digit CER gains

Based on strong Q1 performance, QIAGEN has raised its full-year 2025 adjusted diluted EPS outlook to approximately $2.35 CER (up from $2.28 CER). The company expects to achieve its mid-term adjusted operating income margin target of 31% ahead of the original 2028 timeline.

Positive

• Net sales grew 7% CER to $483M, exceeding 3% guidance
• Adjusted EPS of $0.55 CER beat $0.50 guidance
• QIAstat-Dx sales grew over 35% CER
• QuantiFERON TB test sales increased 15% CER
• Full-year 2025 EPS guidance raised to $2.35 CER from $2.28 CER
• 31% operating margin target to be achieved ahead of 2028 timeline

Negative

• Sample technologies sales declined 1% CER
• Facing headwinds from new U.S. import tariffs

Insights

Financial Analyst

QIAGEN's Q1 2025 preliminary results showcase exceptional operational performance, with $483 million in revenue representing 7% CER growth versus the guided 3%. The adjusted EPS of at least $0.55 significantly outpaced the $0.50 outlook. The 3.1% upward revision in full-year EPS guidance (from $2.28 to $2.35) demonstrates management's increased confidence despite acknowledging headwinds from U.S. import tariffs.

What's particularly impressive is the acceleration of QIAGEN's profitability timeline. The company now expects to exceed its 31% adjusted operating income margin target well before the original 2028 timeline, indicating substantial operational efficiency improvements alongside revenue growth. This dual achievement of growth and margin expansion is relatively rare in the current life sciences environment.

The 1% CER decline in sample technologies amid cautious life sciences customer spending represents the only soft spot, but is more than offset by strong performance across other product categories. This diversified product portfolio provides resilience against sector-specific headwinds while maintaining overall growth momentum.

Diagnostics Industry Expert

QIAGEN's preliminary results reveal exceptional traction in its diagnostic portfolio, with the standout performer being QIAstat-Dx syndromic testing system at over 35% CER growth. This platform's expansion beyond respiratory panels into gastrointestinal and meningitis testing demonstrates the clinical utility of syndromic testing across multiple disease areas.

The 15% CER growth in QuantiFERON shows QIAGEN successfully capturing the secular shift from traditional tuberculin skin tests to more accurate blood-based TB detection. This represents a large, continuing market opportunity as global healthcare systems modernize their TB screening protocols.

High-single-digit gains for both QIAcuity digital PCR and the QIAGEN Digital Insights bioinformatics business reflect growing adoption across both research and clinical applications. Digital PCR in particular represents a strategic growth area as the technology transitions from specialized research applications toward more routine clinical implementation.

While sample technologies saw a minor 1% CER decline, this appears to be market-driven rather than competitive displacement, as similar patterns are visible across the industry due to capital expenditure constraints. The company's strong performance across its more clinically-oriented portfolio effectively mitigates this temporary headwind in research markets.

• Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment

• Full-year 2025 adjusted diluted EPS outlook raised to about $2.35 CER (prior outlook about $2.28 CER)

• On track to exceed 31% CER adjusted operating income margin ahead of 2028 mid-term target

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting strong performances across many growth drivers.

Net sales grew approximately 5% (+7% at constant exchange rates, CER) to about $483 million in Q1 2025, surpassing the previously communicated outlook for about 3% CER growth (4% CER core business excluding discontinued products such as NeuMoDx and Dialunox). Adjusted diluted EPS are expected to be at least $0.55 CER compared to the previously communicated outlook for about $0.50 CER.

Sales of the QuantiFERON latent TB test grew about 15% CER as global adoption continues to shift from the skin test to this proven, modern blood-based test. The QIAstat-Dx syndromic testing system advanced above 35% CER on continued demand for respiratory panels along with growth in gastrointestinal and meningitis testing. The QIAcuity digital PCR system and QIAGEN Digital Insights bioinformatics business both delivered high-single-digit CER gains, reflecting solid adoption across research and clinical applications. Additional growth contributions also came from higher sales of PCR consumables and from OEM products. Sample technologies sales declined 1% CER, reflecting the cautious instrument spending environment among some Life Sciences customers.

Given the positive start to 2025, QIAGEN is raising its adjusted diluted EPS outlook for full-year 2025 in light of the strong sales growth in Q1 and the overall current business trends, which includes expected headwinds from the recently announced U.S. import tariffs and a better-than-expected tax environment.

Full-year 2025, adjusted diluted EPS are now expected to be about $2.35 CER, up from the prior full-year outlook for about $2.28 CER, while reaffirming the goal to improve the adjusted operating income margin to above 30% for the year.

QIAGEN will provide additional perspectives on the outlook for full-year 2025 with the publication of full Q1 2025 results on May 7, 2025.

Additionally, QIAGEN now expects to reach the mid-term adjusted operating income margin goal of at least 31% well ahead of the original 2028 timeline, reflecting the stronger-than-anticipated improvements delivered during 2024 and 2025.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.

Forward-Looking Statement
Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's financial and operational outlook, including its expected Q1 25 and full year net sales, adjusted diluted EPS and adjusted operating income margin, products, development timelines, marketing and / or regulatory approvals, growth strategies, collaborations and operating results are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, tariffs, regulatory processes and logistical dependencies), variability in operating results and allocations between customer classes, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated financial and operational results will materialize as expected. For a comprehensive overview of risks, please refer to the “Risk Factors” contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.

Source: QIAGEN
Category: Corporate

View source version on businesswire.com: https://www.businesswire.com/news/home/20250406144830/en/

Contacts QIAGEN:

Investor Relations

John Gilardi, +49 2103 29 11711

Domenica Martorana, +49 2103 29 11244

e-mail: ir@QIAGEN.com

Public Relations

Thomas Theuringer, +49 2103 29 11826

e-mail: pr@QIAGEN.com

Source: QIAGEN N.V.

FAQ

What are QIAGEN's Q1 2025 revenue and EPS results?

QIAGEN reported Q1 2025 net sales of $483 million (+7% CER) and adjusted diluted EPS of at least $0.55 CER.

How much did QIAGEN raise its 2025 EPS guidance?

QIAGEN raised its full-year 2025 adjusted diluted EPS outlook to $2.35 CER from the previous guidance of $2.28 CER.

Which QIAGEN products showed the strongest growth in Q1 2025?

QIAstat-Dx showed the strongest growth at over 35% CER, followed by QuantiFERON at 15% CER.

What is QIAGEN's operating margin target and timeline?

QIAGEN expects to reach its 31% adjusted operating income margin target well ahead of the original 2028 timeline.

How did QIAGEN's Sample Technologies perform in Q1 2025?

Sample Technologies sales declined 1% CER due to cautious instrument spending among Life Sciences customers.